000			02143 a2200613 4500
005			20250517151821.0
264		0	_c20180130
008			201801s 0 0 eng d
022			_a1742-7843
024	7		_a10.1111/bcpt.12801 _2doi
040			_aNLM _beng _cNLM
100	1		_aParra-Guillen, Zinnia P
245	0	0	_aRole of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment. _h[electronic resource]
260			_bBasic & clinical pharmacology & toxicology _cOct 2017
300			_a309-315 p. _bdigital
500			_aPublication Type: Clinical Trial; Journal Article
650	0	4	_aAged
650	0	4	_aAntineoplastic Agents _xadverse effects
650	0	4	_aCaffeine _xpharmacokinetics
650	0	4	_aCarcinoma, Non-Small-Cell Lung _xdrug therapy
650	0	4	_aChromatography, Liquid
650	0	4	_aCytochrome P-450 CYP1A2 _xgenetics
650	0	4	_aCytochrome P-450 CYP3A _xgenetics
650	0	4	_aDried Blood Spot Testing
650	0	4	_aDrug Monitoring _xmethods
650	0	4	_aErlotinib Hydrochloride _xadverse effects
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aLung Neoplasms _xdrug therapy
650	0	4	_aMale
650	0	4	_aMidazolam _xpharmacokinetics
650	0	4	_aMiddle Aged
650	0	4	_aModels, Biological
650	0	4	_aPharmacogenetics
650	0	4	_aPharmacogenomic Variants
650	0	4	_aPhenotype
650	0	4	_aProspective Studies
650	0	4	_aProtein Kinase Inhibitors _xadverse effects
650	0	4	_aSubstrate Specificity
650	0	4	_aTandem Mass Spectrometry
650	0	4	_aTreatment Outcome
700	1		_aBerger, Peter B
700	1		_aHaschke, Manuel
700	1		_aDonzelli, Massimiliano
700	1		_aWinogradova, Daria
700	1		_aPfister, Bogumila
700	1		_aFrüh, Martin
700	1		_aGillessen, Silke
700	1		_aKrähenbühl, Stephan
700	1		_aKloft, Charlotte
700	1		_aJoerger, Markus
773	0		_tBasic & clinical pharmacology & toxicology _gvol. 121 _gno. 4 _gp. 309-315
856	4	0	_uhttps://doi.org/10.1111/bcpt.12801 _zAvailable from publisher's website
999			_c27115429 _d27115429